Researchers at the NIH and Emory School of Medicine have completed the first minimally invasive coronary artery bypass of the ...

REGENXBIO Inc.  today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler ...

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

Mutare Inc., the authority in enterprise voice security, today announced it has been selected by the American Hospital Association (AHA) as a Preferred Cybersecurity & Risk Provider for Voice Security ...

Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due ...

Costa Rica confirms its first chikungunya case in nine years in a 24-year-old from Esparza, Puntarenas. Health officials intensify fumigations and surveillance ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has ...

Regenxbio Inc. faces pivotal catalysts in 2026, notably RGX-121's FDA decision and RGX-202 Duchenne data, potentially ...

Gradalis announces positive results from phase 2b VITAL trial of Vigil to treat patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer: Dallas Friday, January 16, ...

TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...

Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS in August 2025, the first-and-only FDA-approved treatment for adults with RRP ...

Precigen, Inc. ( PGEN) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 10:30 AM EST ...